SELLAS Life Sciences Group, Inc. (NASDAQ:SLS – Get Free Report) shares fell 6.5% on Thursday . The company traded as low as $11.85 and last traded at $11.96. Approximately 1,390,343 shares changed hands during trading, a decline of 84% from the average daily volume of 8,506,925 shares. The stock had previously closed at $12.79.
Analysts Set New Price Targets
Several equities analysts have recently weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a report on Tuesday, April 21st. Alliance Global Partners reiterated a “buy” rating on shares of SELLAS Life Sciences Group in a research report on Monday, July 6th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $10.00.
Read Our Latest Analysis on SELLAS Life Sciences Group
SELLAS Life Sciences Group Price Performance
SELLAS Life Sciences Group (NASDAQ:SLS – Get Free Report) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.01.
Hedge Funds Weigh In On SELLAS Life Sciences Group
A number of institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC grew its holdings in SELLAS Life Sciences Group by 168.2% during the second quarter. Geode Capital Management LLC now owns 2,200,428 shares of the company’s stock valued at $4,819,000 after purchasing an additional 1,379,988 shares during the period. JPMorgan Chase & Co. purchased a new position in shares of SELLAS Life Sciences Group during the 2nd quarter valued at about $136,000. Rhumbline Advisers purchased a new position in shares of SELLAS Life Sciences Group during the 2nd quarter valued at about $297,000. XTX Topco Ltd bought a new position in shares of SELLAS Life Sciences Group during the 2nd quarter valued at approximately $168,000. Finally, New York State Common Retirement Fund bought a new position in shares of SELLAS Life Sciences Group during the 2nd quarter valued at approximately $108,000. 17.38% of the stock is owned by institutional investors.
SELLAS Life Sciences Group Company Profile
SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.
The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.
Read More
- Five stocks we like better than SELLAS Life Sciences Group
- AST SpaceMobile Stock Sinks as SpaceX Fallout Rattles Space Sector
- Aehr Test Systems Stock Soars on Earnings, Eyes Over 150% Revenue Growth
- TSMC Just Gave AI Chip Bulls Another Reason to Stay Confident
- GE Aerospace Faces a Prove-It Moment in Q2 Earnings
Receive News & Ratings for SELLAS Life Sciences Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SELLAS Life Sciences Group and related companies with MarketBeat.com's FREE daily email newsletter.
